OS9 Antibody

What is OS9 and why is it important in cellular research?

OS9 is a protein highly expressed in osteosarcomas that binds to hypoxia-inducible factor 1 (HIF-1), a key regulator of hypoxic response and angiogenesis, and promotes the degradation of one of its subunits . More importantly, OS9 plays a crucial role in the endoplasmic reticulum-associated degradation (ERAD) pathway, which is responsible for identifying and eliminating misfolded proteins from the ER. OS9 facilitates the turnover of nonnative forms of GRP94, which are hyperglycosylated at cryptic acceptor sites and have altered structure and activity . The protein contains a mannose-6-phosphate receptor homology (MRH) domain that contributes to its function in glycoprotein quality control. Research on OS9 is significant for understanding cellular protein quality control mechanisms and their implications in diseases related to protein misfolding and ER stress.

What are the known isoforms of OS9 relevant to antibody detection?

OS9 exists in multiple isoforms that can be detected at the protein level, primarily OS-9.1 and OS-9.2, which are the most prominently expressed forms . Additional isoforms (OS-9.3, OS-9.4) have been detected as transcripts but have not been fully characterized . These isoforms differ in their binding properties; while OS-9.1 and OS-9.2 can bind to both SEL1L and GRP94, OS-9.3 and OS-9.4 can only bind to SEL1L but not GRP94 . This distinction occurs due to the excision of 15 amino acids (Δ456–470) in OS-9.3 and OS-9.4, which are critical for GRP94 binding . When designing or selecting antibodies for OS9 detection, researchers should consider which isoforms they aim to detect and verify the epitope region targeted by the antibody.

What detection methods are commonly used with OS9 antibodies?

Western blotting (WB) is the most frequently documented application for OS9 antibodies, as evidenced by the Elabscience OS9 Polyclonal Antibody (E-AB-90389) . This antibody has been verified for Western blot analysis across various cell lines with a recommended dilution range of 1:500-1:2000 . The expected molecular weight of OS9 varies from 60 kDa to 75 kDa depending on the isoform and post-translational modifications, though the observed molecular weight in Western blots is typically around 70 kDa . This discrepancy between calculated and observed molecular weight is not uncommon in protein analysis and may be attributed to post-translational modifications, particularly glycosylation, which can significantly alter protein mobility in gel electrophoresis.

How should OS9 antibodies be stored and handled?

According to the manufacturer's recommendations for the OS9 Polyclonal Antibody (E-AB-90389), the antibody should be stored at -20°C where it remains valid for 12 months . It is crucial to avoid freeze/thaw cycles as these can compromise antibody integrity and performance . The antibody is typically shipped with ice packs and should be stored immediately at the recommended temperature upon receipt . The antibody is supplied in a phosphate buffered solution (pH 7.4) containing 0.05% stabilizer and 50% glycerol , which helps maintain its stability during storage. Proper storage and handling of antibodies is essential for reproducible experimental results and extending the usable life of these reagents.

How does OS9 interact with GRP94 and what implications does this have for antibody-based studies?

OS9 interacts with GRP94 through a specific region designated as the GRP94-binding region (94BR), which spans amino acids 443-507 of OS9.1 . This region contains two predicted extended α-helices (aa 448-471 and 485-502) connected by a short, unstructured segment . The interaction is highly specific, as fragments that bisect the 94BR or mutations within this region compromise the binding capacity . Importantly, OS9 preferentially binds to hyperglycosylated forms of GRP94 (hgGRP94), suggesting that glycosylation alters the conformation of GRP94 to expose binding sites for OS9 .

For antibody-based studies, researchers should be aware that certain epitopes might be masked or exposed depending on the glycosylation state and conformational changes of OS9 or its binding partners. For instance, the 9G10 antibody used in studies of GRP94 is more effective at detecting monoglycosylated forms than hyperglycosylated forms, potentially leading to underestimation of hyperglycosylated populations . Additionally, treatments that affect glycosylation (such as tunicamycin) can disrupt the OS9-GRP94 interaction, which could complicate interpretation of co-immunoprecipitation or co-localization studies .

What considerations should be taken when interpreting OS9 antibody results with variable band sizes?

OS9 undergoes glycosylation, which can substantially affect its mobility. The hyperglycosylated forms of proteins typically migrate more slowly than their less glycosylated counterparts . When analyzing OS9 by Western blot, researchers should consider treating samples with glycosidases such as EndoH or PNGase F to assess the contribution of glycosylation to observed band patterns . Additionally, alternative splicing can generate multiple OS9 isoforms with different molecular weights and functional properties . Researchers should use appropriate positive controls and isoform-specific antibodies when available to accurately identify the specific OS9 variants present in their samples.

How can researchers validate the specificity of OS9 antibodies?

Validating antibody specificity is crucial for reliable research outcomes. For OS9 antibodies, several validation approaches are recommended:

• Genetic validation: Utilize cells with CRISPR/Cas9 knockout of OS9 or RNA interference-mediated knockdown as negative controls to confirm specificity .

• Multiple antibodies approach: Use multiple antibodies targeting different epitopes of OS9 to cross-validate findings. If different antibodies show consistent results, specificity is more likely .

• Recombinant protein controls: Include purified recombinant OS9 protein as a positive control in immunoblotting experiments .

• Blocking peptides: Pre-incubate the antibody with its immunogen (e.g., recombinant fusion protein of human OS9) to demonstrate signal elimination in competitive binding assays .

• Species cross-reactivity testing: Verify the antibody's performance across different species. The Elabscience OS9 Polyclonal Antibody, for example, has been validated for reactivity with human and mouse samples .

• Batch validation: Given concerns about batch-to-batch variability in antibodies, researchers should validate each new batch against previously validated lots, particularly for polyclonal antibodies .

What are the optimal protocols for using OS9 antibodies in Western blotting?

When using OS9 antibodies for Western blotting, several methodological considerations can optimize detection:

• Sample preparation: Since OS9 is primarily localized in the endoplasmic reticulum lumen , efficient cell lysis and membrane solubilization are essential. Use lysis buffers containing detergents compatible with membrane protein extraction.

• Protein denaturation: Complete denaturation is crucial for exposing all epitopes. For OS9, standard SDS-PAGE conditions with reducing agents are typically sufficient.

• Antibody dilution: For the Elabscience OS9 Polyclonal Antibody, a dilution range of 1:500-1:2000 is recommended for Western blotting . The optimal dilution should be determined empirically for each experimental system.

• Detection of glycosylated forms: Researchers interested in distinguishing between differently glycosylated forms of OS9 should consider parallel samples treated with glycosidases like EndoH or PNGase F .

• Molecular weight considerations: The calculated molecular weight of OS9 ranges from 60-75 kDa depending on the isoform, but the observed band is typically around 70 kDa . This discrepancy should be noted when interpreting results.

• Blocking and washing: Standard blocking with BSA or non-fat milk and thorough washing steps are important to minimize background and non-specific binding.

What controls should be included when working with OS9 antibodies?

Proper controls are essential for reliable interpretation of experiments using OS9 antibodies:

• Positive controls: Include cell lines known to express OS9, such as those verified by the antibody manufacturer . For the Elabscience antibody, various cell lines have been verified for Western blotting applications.

• Negative controls: Ideally, include OS9 knockout or knockdown samples. Alternatively, use cell lines with minimal OS9 expression as comparative controls.

• Loading controls: Include housekeeping proteins as loading controls to normalize OS9 expression levels across samples.

• Glycosylation controls: When studying OS9's role in glycoprotein quality control, include samples treated with glycosylation inhibitors (like tunicamycin) or glycosidases (EndoH, PNGase F) to assess glycosylation effects .

• Antibody specificity controls: Occasionally include pre-absorption controls with the immunizing antigen to verify signal specificity.

• Isoform controls: If studying specific OS9 isoforms, include controls expressing only the isoform of interest, if possible.

How can researchers troubleshoot inconsistent results with OS9 antibodies?

When encountering inconsistent results with OS9 antibodies, consider the following troubleshooting approaches:

• Batch variability: Antibody performance can vary between batches, particularly for polyclonal antibodies . Record and track batch numbers and consider validating new batches against previously successful ones.

• Epitope accessibility: The conformation and post-translational modifications of OS9 can affect epitope accessibility. Ensure complete denaturation for Western blotting or optimize fixation methods for immunocytochemistry.

• Cross-reactivity: Verify that the observed signal is specific to OS9 using appropriate controls. Some antibodies may cross-react with similar proteins.

• Sample preparation issues: Inconsistent results may stem from variations in sample preparation. Standardize lysis conditions, protein quantification methods, and handling procedures.

• Glycosylation heterogeneity: OS9 exists in various glycosylated forms, which can affect antibody recognition . Consider treating samples with glycosidases to eliminate this variable.

• Storage and handling: Improper antibody storage or excessive freeze-thaw cycles can degrade antibody quality. Follow manufacturer's recommendations for storage .

How are OS9 antibodies used to study protein quality control mechanisms?

OS9 antibodies are valuable tools for investigating endoplasmic reticulum-associated degradation (ERAD) and protein quality control mechanisms. OS9 facilitates the turnover of nonnative forms of GRP94 that are hyperglycosylated and structurally altered . By using OS9 antibodies in co-immunoprecipitation experiments, researchers can identify and characterize interactions between OS9 and various ERAD components or substrates.

Studies have demonstrated that OS9 interacts with the HRD3-HRD1 ubiquitin ligase complex (or SEL1L-HRD1 in mammals) to recognize and target misfolded proteins for degradation . OS9 antibodies can be employed to monitor changes in these interactions under different cellular conditions, such as ER stress or in disease models characterized by protein misfolding.

Importantly, OS9 recognizes ERAD substrates and GRP94 through distinct regions . The minimal OS9 region (aa 443-507) necessary for GRP94 interaction does not bind to ERAD substrates like NHK . This suggests that OS9 has multiple functional domains that simultaneously interact with different partners. Researchers can use domain-specific antibodies or epitope tagging approaches in conjunction with OS9 antibodies to dissect these complex interactions.

What insights have OS9 antibodies provided about glycoprotein quality control?

OS9 antibodies have contributed significantly to our understanding of glycoprotein quality control in the endoplasmic reticulum. Research using these antibodies has revealed that OS9 contains a mannose-6-phosphate receptor homology (MRH) domain, similar to its yeast homolog YOS9 . This domain is crucial for recognizing specific glycan structures on misfolded proteins targeted for degradation.

Interestingly, studies with OS9 antibodies have shown that while OS9 preferentially binds to hyperglycosylated GRP94, this interaction is independent of its MRH domain . This suggests that OS9 uses different mechanisms to recognize various targets: glycan-dependent recognition for some ERAD substrates and structural recognition for others.

The interaction between OS9 and GRP94 is also glycosylation-dependent, as treatment with the glycosylation inhibitor tunicamycin markedly reduces their association . This finding highlights the importance of glycosylation in modulating protein-protein interactions within the ER quality control system. OS9 antibodies have thus helped elucidate the complex interplay between protein structure, glycosylation, and quality control mechanisms in the cell.

How can OS9 antibodies contribute to cancer research?

OS9 antibodies hold significant potential for cancer research, particularly in studying osteosarcomas where OS9 is highly expressed . OS9 binds to hypoxia-inducible factor 1 (HIF-1), a key regulator of the hypoxic response and angiogenesis, and promotes the degradation of one of its subunits . This connection to hypoxia signaling places OS9 at the intersection of two critical processes in cancer biology: protein quality control and hypoxic adaptation.

Researchers can use OS9 antibodies to investigate alterations in OS9 expression, localization, or interaction patterns across different cancer types and stages. Such studies might reveal how changes in the ERAD pathway contribute to cancer cell survival under stress conditions or how altered protein quality control affects tumor progression.

Additionally, given OS9's involvement in the degradation of misfolded proteins, it may play a role in modulating the sensitivity of cancer cells to proteotoxic stress-inducing therapies. OS9 antibodies could help identify patient populations likely to respond to such treatments based on OS9 expression patterns or functional status.

What is the potential role of OS9 antibodies in studying neurodegenerative diseases?

Neurodegenerative diseases often involve protein misfolding and aggregation, making the ERAD pathway a relevant area of study. As a key component of this pathway, OS9 could influence the cell's ability to clear potentially toxic protein species. OS9 antibodies can help researchers investigate whether alterations in OS9 function contribute to the accumulation of misfolded proteins in conditions like Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis.

By examining OS9 expression, localization, and interactions in cellular and animal models of neurodegeneration, researchers might identify novel therapeutic targets within the protein quality control machinery. Additionally, OS9 antibodies could be used to assess whether genetic variants of OS9 are associated with altered risk or progression of neurodegenerative diseases.

This research direction is particularly promising given the established link between endoplasmic reticulum stress, impaired protein quality control, and neurodegeneration. OS9 antibodies provide a valuable tool for dissecting these complex relationships at the molecular level.